A study has found that Alpha-Stim, a drug-free cranial electrotherapy stimulation (CES) device, is effective in treating the pain, anxiety and depression symptoms that advanced cancer patients often suffer with.

The Alpha-Stim is a handheld, non-invasive medical device which uses low-level electrical currents to treat anxiety, depression, and insomnia. It was initially cleared by the FDA in 1992 as a prescriptive, non-invasive treatment. CES has an extensive safety record with few side effects (less than 1%) and scientific evidence of the significant results patients can achieve by using it.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Patients with advanced cancer are often routinely prescribed medications for pain, anxiety, insomnia and depression. A study by MD Anderson Cancer Center, Texas, examined the safety and efficacy of this non-drug treatment option specifically for this patient type and concluded that Alpha-Stim is extremely effective, with no serious adverse effects and no risk of addiction, unlike opioid treatment options.

The study found that advanced cancer patients who were treated with CES via the Alpha-Stim for just four weeks saw significant improvement of pain, anxiety, and depression symptoms, as well as insomnia relief. It is the first published study regarding this kind of research on patients with advanced cancer.

The inventor of the Alpha-Stim technology and chairman of Electromedical Products International (EPI), Daniel L. Kirsch, PhD, said: “I am very happy, but not surprised to see that Alpha-Stim technology has been able to help advanced cancer patients on multiple issues during the most difficult period in their lives. It has already been recognized as the preferred drug-free choice for a wide variety of people, from veterans fighting pain and depression to dental patients with high anxiety and many others.”

Jeffrey Marksberry, MD, chief science and clinical officer at EPI, added: “We are very proud and excited about this independent study from MD Anderson. It further corroborates the previous independent studies that found that Alpha-Stim is a viable treatment option for pain, anxiety, insomnia and depression, even in one of the most difficult-to-treat patient populations. Not only is it viable, but it is also faster, safer and more effective than pharmaceuticals, without the addictive qualities, and in the long run less expensive.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact